Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
暂无分享,去创建一个
Stefan Mundlos | Denise Horn | Dirk Schnabel | Kerstin Kutsche | Salmo Raskin | Martin Zenker | D. Horn | S. Mundlos | S. Raskin | M. Zenker | K. Kutsche | C. Kratz | R. Korinthenberg | P. Meinecke | R. Koenig | A. Quante | Rudolf Korinthenberg | Christian P Kratz | M. Kreiss-Nachtsheim | S. Morlot | D. Schnabel | Peter Meinecke | Katarina Lehmann | Anne S Quante | Rainer Koenig | Lars-Erik Wehner | Anna Leana Schulz | Helmut Barth | Dagmar Hansmann | Martina Kreiss-Nachtsheim | Susanne Morlot | L. Wehner | K. Lehmann | A. Schulz | D. Hansmann | H. Barth | Dagmar Hansmann
[1] D. Brunoni,et al. CFC index for the diagnosis of cardiofaciocutaneous syndrome. , 2002, American journal of medical genetics.
[2] B. Gelb,et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. , 2006, American journal of human genetics.
[3] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[4] R. Foà,et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.
[5] H. Ropers,et al. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.
[6] P. Schultz,et al. Probing the role of loop 2 in Ras function with unnatural amino acids. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] E. Mariman,et al. Clinical and molecular studies in a large Dutch family with Noonan syndrome. , 1994, American journal of medical genetics.
[8] R. Hennekam,et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.
[9] Bruce D Gelb,et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.
[10] R. Hennekam. Costello syndrome: An overview , 2003, American journal of medical genetics. Part C, Seminars in medical genetics.
[11] W. Reardon,et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases , 2005, Journal of Medical Genetics.
[12] E. Zackai,et al. HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation , 2006, American journal of medical genetics. Part A.
[13] Pablo Rodriguez-Viciana,et al. Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.
[14] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[15] B. Neel,et al. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.
[16] D. Wieczorek,et al. Cardio‐facio‐cutaneous (CFC) syndrome — a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome , 1997, Clinical genetics.
[17] I. Vetter,et al. The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.
[18] J. Opitz,et al. The cardiofaciocutaneous syndrome , 2006, Journal of Medical Genetics.
[19] C. Der,et al. Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] C. Herrmann. Ras-effector interactions: after one decade. , 2003, Current opinion in structural biology.
[21] Bruce D Gelb,et al. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. , 2006, Human molecular genetics.
[22] B. Neel,et al. Stops along the RAS pathway in human genetic disease , 2006, Nature Medicine.
[23] H. Ropers,et al. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.
[24] Suk Woo Nam,et al. BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.
[25] K. Gripp. Tumor predisposition in Costello syndrome , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.
[26] H. Nagai,et al. Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. , 2002, Japanese journal of clinical oncology.
[27] W. Kress,et al. Genotype-phenotype correlations in Noonan syndrome. , 2004, The Journal of pediatrics.
[28] Yukichi Tanaka,et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.
[29] K. Rauen. Distinguishing Costello versus cardio‐facio‐cutaneous syndrome: BRAF mutations in patients with a Costello phenotype , 2006, American journal of medical genetics. Part A.
[30] M. Teitell,et al. Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy , 2005 .
[31] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[32] J. Stone,et al. Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction , 1993, Molecular and cellular biology.